September 2, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria
 

Tokyo, Aug 1, 2013 (JCN) - Daiichi Sankyo announced that it will expand its Take a New challenge for Drug diScovery (TaNeDS) Global Program, a collaborative drug discovery program with universities and research institutions based in Japan, to Germany, Switzerland and Austria.

As part of the program, Daiichi Sankyo is seeking to work with innovative partners for research that could result in novel drug discovery candidates and novel new drugs.

The TaNeDS program is open to researchers of any nationality employed by universities, research institutes and start-up companies in Germany, Switzerland and Austria who can conduct research with projects that align with Daiichi Sankyo's research areas of interest.

Those areas include novel biologic agents (antibody drugs, etc.) for treatment of cancer, small-molecule cancer therapeutics, novel drug treatments for diabetes and complications of diabetes, novel mechanisms for genetic disorders, novel target molecules and delivery systems for nucleic acid treatments, and technology for protein x-ray crystallography.

Daiichi Sankyo and U3 Pharma GmbH (Munich, Germany), a wholly owned subsidiary of Daiichi Sankyo, will select institutions that match their research needs and demonstrate originality, potential and promise as drug discovery candidates.

The TaNeDS collaborative drug discovery project was launched in Japan in 2011 to help discover new lines of research through open innovation. Many researchers in Japan have applied to the program and research on selected themes is currently being conducted.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Daiichi Sankyo  News  
  Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria  (Aug 1, 2013)
  Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy  (Feb 15, 2013)
  Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign  (Dec 20, 2012)
  Daiichi Sankyo, Ranbaxy Launch Psteoporosis Medication EVISTA in Romania  (Sept 2, 2009)
  Daiichi Sankyo Files Application for Dysuria Treatment KMD-3213 in China  (Jan 8, 2009)
  Daiichi Sankyo and Ranbaxy Move Forward Toward The Completion of the Landmark Deal  (Oct 20, 2008)
  Daiichi Sankyo's Tender Offer for Ranbaxy Ends in Success  (Oct 17, 2008)
  Shionogi to Acquire U.S. Drug Maker Sciele Pharma  (Sept 1, 2008)
  Daiichi Sankyo to Buy Indian Drug Giant Ranbaxy  (June 11, 2008)
  Daiichi Sankyo to Acquire German Biomedical Firm  (May 21, 2008)



 Recent  Biotech News   
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)

More Biotech news...

 Recent  Drugs & OTC News   
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)